Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MBX Biosciences, Inc. (MBX)

MBX Biosciences Q2 net loss widens to $37.1 million; cash totals $418.6 million

Mixed Impact 4 of 5 earnings Written later

MBX Biosciences reported a second-quarter 2026 net loss of $37.1 million, up from $19.4 million a year earlier, as research and development and general and administrative expenses rose. The company said its $418.6 million in cash and investments is expected to fund operations into 2029, and it reiterated timelines for a Phase 3 start in Q3 2026 and Phase 1 data for MBX 4291 in Q4 2026.

Key points

  • Q2 2026 net loss was $37.1 million, or $0.78 per share, versus a net loss of $19.4 million, or $0.58 per share, in Q2 2025.
  • R&D expenses were $31.0 million versus $17.7 million; G&A expenses were $9.9 million versus $4.1 million.
  • Cash, cash equivalents and marketable securities were $418.6 million as of June 30, 2026, expected to last into 2029.
  • Steve Hoerter was appointed Chairman and Chief Executive Officer, succeeding Kent Hawryluk; John Smither was named Chief Financial Officer.

The filing

CompanyMBX Biosciences, Inc. (MBX)
Form8-K, current report
Filed with the SECAug 6, 2026, 8:03 AM ET
Accession number0001193125-26-336841

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.